WO2012177008A3 - 마이크로 ｒｎａ를 포함하는 색소형성 조절용 조성물 - Google Patents

마이크로 ｒｎａ를 포함하는 색소형성 조절용 조성물 Download PDF

Info

Publication number
WO2012177008A3
WO2012177008A3 PCT/KR2012/004645 KR2012004645W WO2012177008A3 WO 2012177008 A3 WO2012177008 A3 WO 2012177008A3 KR 2012004645 W KR2012004645 W KR 2012004645W WO 2012177008 A3 WO2012177008 A3 WO 2012177008A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sequence number
mirna
chromogenesis
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004645
Other languages
English (en)
French (fr)
Other versions
WO2012177008A2 (ko
Inventor
김규한
최현정
빈범호
이태룡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to HK14112601.0A priority Critical patent/HK1199063B/xx
Priority to CN201280030667.5A priority patent/CN104169420B/zh
Priority to US14/126,505 priority patent/US9303261B2/en
Publication of WO2012177008A2 publication Critical patent/WO2012177008A2/ko
Publication of WO2012177008A3 publication Critical patent/WO2012177008A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 서열번호 1의 miRNA. 또는 서열번호 1의 miRNA에 상보적인 염기서열을 갖고 상기 miRNA에 하이브리드될 수 있는 것을 특징으로 하는 서열번호 2의 안티센스 핵산 분자를 포함하는 미백효과 또는 백모 방지 조성물을 제공한다. 또한, 본 발명은 시험물질에 대한 색소형성을 조절할 뿐만 아니라 색소형성 유전자의 발현 조절 물질을 스크리닝하는 방법으로서, 서열번호 1의 miRNA 또는 서열번호 2인 안티센스 핵산 분자를 세포에 트랜스펙션시키는 단계; 상기 세포에 시험 물질을 처리하는 단계; 및 상기 시험물질이 색소형성 유전자의 발현을 억제하는지 또는 촉진하는지 여부를 확인하는 단계; 세포의 색이 변화하는지 확인하는 단계;를 포함하는 것을 특징으로 하는 색소형성 조절 및 색소형성 유전자의 발현 조절 물질 스크리닝 방법을 제공한다. 본 발명의 조성물 및 스크리닝 방법은 미백효과 또는 백모 방지 효과를 위해 사용될 수 있다.
PCT/KR2012/004645 2011-06-23 2012-06-13 마이크로 ｒｎａ를 포함하는 색소형성 조절용 조성물 Ceased WO2012177008A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HK14112601.0A HK1199063B (en) 2011-06-23 2012-06-13 Composition for controlling chromogenesis including microrna
CN201280030667.5A CN104169420B (zh) 2011-06-23 2012-06-13 包含miRNA的调节色素形成的组合物
US14/126,505 US9303261B2 (en) 2011-06-23 2012-06-13 Composition for controlling chromogenesis including microRNA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110061107 2011-06-23
KR10-2011-0061107 2011-06-23

Publications (2)

Publication Number Publication Date
WO2012177008A2 WO2012177008A2 (ko) 2012-12-27
WO2012177008A3 true WO2012177008A3 (ko) 2013-02-14

Family

ID=47423053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004645 Ceased WO2012177008A2 (ko) 2011-06-23 2012-06-13 마이크로 ｒｎａ를 포함하는 색소형성 조절용 조성물

Country Status (4)

Country Link
US (1) US9303261B2 (ko)
KR (1) KR101938548B1 (ko)
CN (1) CN104169420B (ko)
WO (1) WO2012177008A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102682748B1 (ko) * 2016-09-23 2024-07-15 (주)아모레퍼시픽 Sh3bp4 억제 물질을 포함하는 피부 미백용 조성물 및 sh3bp4 억제 물질의 스크리닝 방법
KR102109976B1 (ko) 2017-07-25 2020-05-13 동국대학교 산학협력단 아르기나제 2 억제제를 유효성분으로 함유하는 색소형성 억제용 조성물
CN111819185A (zh) 2017-12-15 2020-10-23 旗舰创业创新第六有限责任公司 包含环状多核糖核苷酸的组合物及其用途
CN111041082B (zh) * 2018-10-11 2023-11-07 伽蓝（集团）股份有限公司 一种以皮肤光老化靶标筛选改善皮肤光老化的活性物的方法及改善皮肤光老化的活性物
MA55082A (fr) * 2019-03-01 2022-01-05 Flagship Pioneering Innovations Vi Llc Compositions, procédés, et kits pour l'administration de polyribonucléotides
AU2020232238B2 (en) * 2019-03-01 2025-10-30 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
WO2020198403A2 (en) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
CN110448567A (zh) * 2019-08-26 2019-11-15 佳木斯大学 miRNA125b纳米粒子的应用
WO2022182188A1 (ko) * 2021-02-25 2022-09-01 (주)바이오니아 이중가닥 mirna를 유효성분으로 포함하는 모발의 회백색화 개선, 발모 촉진 및/또는 탈모의 예방 또는 개선용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
US20110143948A1 (en) * 2008-02-01 2011-06-16 Ranjan Perera Molecular signatures and biomarkers associated with melanoma and methods of use thereof
KR20110068061A (ko) * 2009-12-15 2011-06-22 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447370B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
GB0502042D0 (en) * 2005-02-01 2005-03-09 Univ Glasgow Materials and methods for diagnosis and treatment of chronic fatigue syndrome
WO2008036776A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
TWI382849B (zh) * 2007-10-29 2013-01-21 Mello Biotech Taiwan Co Ltd 產生藉由基因靜默效應以用於皮膚維護之化妝品的方法以及編碼基因靜默效應物之基因重組核苷酸
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
CN101942502B (zh) * 2009-12-24 2014-09-17 北京命码生科科技有限公司 胰腺癌标记物及其检测方法、试剂盒和生物芯片

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
US20110143948A1 (en) * 2008-02-01 2011-06-16 Ranjan Perera Molecular signatures and biomarkers associated with melanoma and methods of use thereof
KR20110068061A (ko) * 2009-12-15 2011-06-22 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID TS WU ET AL.: "Mir 434-5p mediates skin whitening and lightening", CLIN COSMET INVESTING DERMATOL., vol. 1, 2008, pages 19 - 35 *
Z. ZHU ET AL.: "MicroRNA-25 functions in regulation of pigmentation by targeting the transcription factor MITF in alpaca (Lama pacos) skin", DOMESTIC ANIMAL ENDOCRINOLOGY, vol. 38, 2010, pages 200 - 209 *

Also Published As

Publication number Publication date
CN104169420B (zh) 2016-05-04
HK1199063A1 (zh) 2015-06-19
KR20130001123A (ko) 2013-01-03
US9303261B2 (en) 2016-04-05
US20140134636A1 (en) 2014-05-15
WO2012177008A2 (ko) 2012-12-27
KR101938548B1 (ko) 2019-01-15
CN104169420A (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
WO2012177008A3 (ko) 마이크로 ｒｎａ를 포함하는 색소형성 조절용 조성물
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009036933A3 (de) Herabregulation der genexpression mittels nukleinsäure-beladener virusähnlicher partikel
WO2009135074A3 (en) Microorganisms for the production of methacrylic acid
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2009148560A8 (en) Methods and compositions for nucleic acid sequencing
WO2009126250A3 (en) Reprogramming a cell by inducing a pluripotent gene through rna interference
FI3604532T3 (fi) Uusia crispr-entsyymejä ja järjestelmiä
WO2009086428A3 (en) Methods and compositions for increasing gene expression
WO2017156015A3 (en) Micrornas and methods of their use
WO2009111658A3 (en) Compositions and methods for inhibiting expression of eg5 and vegf genes
MX363017B (es) Métodos y productos para la expresión de proteínas en células.
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
WO2008131191A8 (en) Nucleic acids hybridizable to micro rna and precursors thereof
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2012136898A3 (en) Novel cutinases, their production and uses
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
WO2011014740A8 (en) Methods and compositions for identifying and validating modulators of cell fate
WO2011163531A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2010135714A3 (en) Methods for modulating adipocyte expression using microrna compositions
ATE552345T1 (de) Verfahren zur herstellung von fermentationsprodukten
Li et al. Dynamic regulation of small RNAome during the early stage of cardiac differentiation from pluripotent embryonic stem cells
WO2013040393A3 (en) Genes contributing to survival of cancer cells
WO2009039743A8 (zh) 一种抑制酪氨酸酶基因表达的siRNA及组合物和应用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280030667.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12802909

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14126505

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 10-04-2014

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 10-04-2014

122 Ep: pct application non-entry in european phase

Ref document number: 12802909

Country of ref document: EP

Kind code of ref document: A2